Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
VEYVONDI IU (Shire Australia Pty Ltd)
Product name
VEYVONDI IU
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
173 working days (175)
Active ingredients
vonicog alfa
Registration type
NCE/NBE
Indication
VEYVONDI (powder for injection with solvent vials) is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated, for the:
- treatment of haemorrhage and surgical bleeding
- prevention of surgical bleeding.
VEYVONDI should not be used in the treatment of Haemophilia A.